Proactive Investors - Run By Investors For Investors

Cancer doctors offer key takeaways from American Society of Clinical Oncology conference

Merck's lung cancer-fighting drug Keytruda has just been approved for the treatment of cervical cancer
Cancer in a headline
Attendees at the ASCO conference were also bullish on the combination of Opdivo with Yervoy

An important takeaway to come out of the American Society of Clinical Oncology conference early this month is that Merck’s lung cancer-fighting drug Keytruda is quite similar in its efficacy and safety to Bristol-Myers Squibb Co’s (NYSE:BY) Opdivo.

This insight is the view of two attendees at the ASCO conference,  Dr. Jack Goldberg, chief of hematology and medical oncology at Penn Presbyterian Medical Center and Dr. Igor Genkin who practices in the Bronx with an emphasis on biomarker development.

Both offered opinions on the conference to Oppenheimer analysts.

“These doctors view Keytruda and Opdivo as very similar in terms of efficacy and safety with differences arising from their respective study designs in lung cancer,” wrote Oppenheimer analysts.

The stage three data for AstraZeneca PLC’s (NYSE:AZN) rival drug Imfimzi is also seen by both doctors as compelling and the data on the drug provided at ASCO will likely accelerate utilization, the doctors predict.

Another drug therapy both Goldberg and Genkin are positive on is the combination of Opdivo with Yervoy in lung cancer patients.

Both believe that precision oncology is likely to become “very impactful to their practices” as new emphasis is placed on targeting mutations rather than the cells of origin. They are also bullish on the use of biomarkers in their practices and look forward to future clinical studies.

In other news today, Merck (NYSE:MRK) confirmed that the US Food and Drug Administration has also approved Keytruda, a popular weapon against lung cancer, for the treatment of patients with recurrent or metastatic cervical cancer.

View full BMY profile View Profile

Bristol-Myers Squibb Co Timeline

Related Articles

harley street
May 10 2019
Work at Advanced Onco’s Harley Street facility is due to complete within the next few months, and the first patient treated by LIGHT is slated for the second half of 2020
LX2 analyzer
May 07 2019
Armed with promising study results and proven technology, LexaGene is getting ready to launch the LX2 Genetic Analyzer to underserved markets valued at an estimated US$40 billion
PT exercises
December 19 2018
The Californian company is a bet on an industry that is in need of transformation
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use